Selected Prognostic Factors of Malignant Uveal Melanoma
Authors:
Z. Svetlošáková 1; V. Krásnik 1; H. Gergišáková 2; P. Babál 2; P. Kusenda 1
Authors place of work:
Klinika oftalmológie LFUK, Bratislava, prednosta doc. MUDr. Vladimír Krásnik, PhD.
1; Ústav patologickej anatómie LFUK, prednosta prof. MUDr. Ľudovít Danihel, PhD.
2
Published in the journal:
Čes. a slov. Oftal., 68, 2012, No. 1, p. 38-42
Category:
Original Article
Summary
Malignant uveal melanoma is the most common intraocular tumor in adults. Despite very good local treatment results, patients` survival has not improved in the last decades.
The main cause of death is metastatic spread, which occurs with a variable time delay after tumor discovery in 50 % of patients. After metastasis development the mean survival rate decreases to less than 6 months.
Progression to metastatic disease is associated with different prognostic factors. The spectrum of conventional clinical and histopathologic prognostic factors like age, tumor size, location, extrascleral growth, histopathologic cell type, vascularisation, invasion of sclera, etc., has been enlarged by using new immunological, molecular, immunohistochemical and cytogenetical methods.
Current research also focuses on development of an adjuvant systemic therapy which could delay or prevent metastasis development in high-risk patients. It is necessary to determine reliable prognostic factors in order to select potential candidates for such a systemic treatment. In this article we present a short overview of known prognostic factors of uveal melanoma.
Key words:
malignant uveal melanoma, metastasis, prognostic factors
Zdroje
1. Aalto, Y., Eriksson, L., Seregard, S. et al.: Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma, Invest Ophthalmol Vis Sci, 42, 2001, 2: 313–7.
2. Al-Jamal, R.T., Kivela, T.: KI-67 immunopositivity in choroidal and ciliary body melanoma with respect to nucleolar diameter and other prognostic factors, Curr Eye Res, 31, 2006, 1: 57–67.
3. Anastassiou, G., Schilling, H., Stang, A. et al.: Expression of the cell adhesion molecules ICAM-1, VCAM-1 and NCAM in uveal melanoma: a clinicopathological study, Oncology, 58, 2000, 1: 83–8.
4. Bedikian, A.Y.: Metastatic uveal melanoma therapy: current options, Int Ophthalmol Clin, 46, 2006, 1: 151–66.
5. Beutel, J., Wegner, J., Wegner, R. et al.: Possible implications of MCAM expression in metastasis and non-metastatic of primary uveal melanoma patients, Curr Eye Res, 34, 2009, 11: 1004–9.
6. Callender, G.R.: Malignant melanotic tumors of the eye: a study of histologic types in 111 cases, Trans Am Acad Ophthalmol Otolaryngol, 36, 1931, 131-42.
7. Campbell, R.J., Sobin, L.H.: WHO-Histological typing of tumours of the eye and its adnexa, New York, Springer, 1998, 115s.
8. Diener-West, M., Reynolds, S.M., Agugliaro, D.J. et al.: Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23, J Clin Oncol, 22, 2004, 12: 2438–44.
9. Diener-West, M., Reynolds, S.M., Agugliaro, D.J. et al.: Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26, Arch Ophthalmol, 123, 2005, 12: 1639–43.
10. Edge, S.B., Byrd, D.R., Compton, C.C. et al.: AJCC Cancer Staging Handbook, New York, Springer, 2010, 730 s.
11. Erol, N., Oner, U., Artan, S. et al.: Chromosomal abnormalities, p53 and Bcl-2 expression and clinical outcome in choroidal melanoma, Melanoma Res, 14, 2004, 6: 473–8.
12. Eskelin, S., Pyrhonen, S., Summanen, P. et al.: Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment, Ophthalmology, 107, 2000, 8: 1443–9.
13. Folberg, R., Pe’er, J., Gruman, L.M. et al.: The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study, Hum Pathol, 23, 1992, 11: 1298–305.
14. Furdová, A.: Nové trendy v liečbe malígneho melanómu uvey. In Rozsíval, P. (Ed), Trendy soudobé oftalmologie, svazek 4, Galén, 2007, s.13–35.
15. Furdová, A., Böhmer, D., Blaško, M. et al.: Genetika uveálnych melanómov (monozómia 3) – porovnanie karyotypu z buniek nádoru, limbálnych kmeňových buniek a periférnej krvi (prvé výsledky). In (Ed), 6. bilaterálne slovensko-české oftalmologické sympózium – Zborník Bratislava, Slovenská oftalmologická spoločnosť, 2011, s. 26–27.
16. Furdová, A., Chynoranský, M., Krajčová, P.: Orbital melanoma, Bratisl Lek Listy, 112, 2011, 8: 466–8.
17. Furdová, A., Oláh, Z.: Malígny melanóm v uveálnom trakte, Bratislava, Asklepios, 2002, 175 s.
18. Furdová, A., Oláh, Z.: Nádory oka a okolitých štruktúr, Brno, Akademické nakladatelství CERM, 2010, 151 s.
19. Furdová, A., Slezák, P., Chorváth, M. et al.: No differences in outcome between radical surgical treatment (enucleation) and stereotactic radiosurgery in patients with posterior uveal melanoma, Neoplasma, 57, 2010, 4: 377–81.
20. Furdová, A., Strmeň, P., Waczulíková, I. et al.: One-day session LINAC-based stereotactic radiosurgery of posterior uveal melanoma, Eur J Ophthalmol, 2011, Published online: 18/04/2011, DOI 10.5301/EJO.2011.7733.
21. Geisse, L.J., Robertson, D.M.: Iris melanomas, Am J Ophthalmol, 99, 1985, 6: 638-48.
22. Ghazvini, S., Char, D.H., Kroll, S. et al.: Comparative genomic hybridization analysis of archival formalin-fixed paraffin-embedded uveal melanomas, Cancer Genet Cytogenet, 90, 1996, 2: 95–101.
23. Gragoudas, E.S.: Proton beam irradiation of uveal melanomas: the first 30 years. The Weisenfeld Lecture, Invest Ophthalmol Vis Sci, 47, 2006, 11: 4666–73.
24. Hussein, M.R.: The relationships between p53 protein expression and the clinicopathological features in the uveal melanomas, Cancer Biol Ther, 4, 2005, 1: 57–9.
25. Janssen, K., Kuntze, J., Busse, H. et al.: p53 oncoprotein overexpression in choroidal melanoma, Mod Pathol, 9, 1996, 3: 267–72.
26. Jensen, O.A.: Malignant melanoma of the iris. A 25-year analysis of Danish cases, Eur J Ophthalmol, 3, 1993, 4: 181–8.
27. Maniotis, A.J., Folberg, R., Hess, A. et al.: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry, Am J Pathol, 155, 1999, 3: 739–52.
28. McLean, I.W., Keefe, K.S., Burnier, M.N.: Uveal melanoma. Comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size, Ophthalmology, 104, 1997, 5: 777–80.
29. Onken, M.D., Worley, L.A., Ehlers, J.P. et al.: Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death, Cancer Res, 64, 2004, 20: 7205–9.
30. Petrausch, U., Martus, P., Tonnies, H. et al.: Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases, Eye (Lond), 22, 2008, 8: 997–1007.
31. Sato, T.: Locoregional management of hepatic metastasis from primary uveal melanoma, Semin Oncol, 37, 2010, 2: 127–38.
32. Seregard, S., Oskarsson, M., Spangberg, B.: PC-10 as a predictor of prognosis after antigen retrieval in posterior uveal melanoma, Invest Ophthalmol Vis Sci, 37, 1996, 7: 1451–8.
33. Shields, C.L., Shields, J.A., Materin, M. et al.: Iris melanoma: risk factors for metastasis in 169 consecutive patients, Ophthalmology, 108, 2001, 1: 172–8.
34. Scholes, A.G., Damato, B.E., Nunn, J. et al.: Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival, Invest Ophthalmol Vis Sci, 44, 2003, 3: 1008–11.
35. Singh, A.D., Topham, A.: Incidence of uveal melanoma in the United States: 1973-1997, Ophthalmology, 110, 2003, 5: 956–61.
36. Singh, A.D., Topham, A.: Survival rates with uveal melanoma in the United States: 1973-1997, Ophthalmology, 110, 2003, 5: 962–5.
37. Singh, A.D., Turell, M.E., Topham, A.K.: Uveal melanoma: trends in incidence, treatment, and survival, Ophthalmology, 118, 2011, 9: 1881–5.
38. Sisley, K., Parsons, M.A., Garnham, J. et al.: Association of specific chromosome alterations with tumour phenotype in posterior uveal melanoma, Br J Cancer, 82, 2000, 2: 330–8.
39. Tokošová, E., Hermanová, M., Uhmannová, R. et al.: Immunohistochemical detection of the gene p53 and p21 expression in cells of the malignant melanoma of the uvea, Čes Slov Oftalmol, 64, 2008, 4: 153–6.
40. van Gils, W., Lodder, E.M., Mensink, H.W. et al.: Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis, Invest Ophthalmol Vis Sci, 49, 2008, 10: 4254–62.
41. Whelchel, J.C., Farah, S.E., McLean, I.W. et al.: Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma, Invest Ophthalmol Vis Sci, 34, 1993, 8: 2603–6.
42. Worley, L.A., Onken, M.D., Person, E. et al.: Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma, Clin Cancer Res, 13, 2007, 5: 1466–71.
Štítky
OphthalmologyČlánok vyšiel v časopise
Czech and Slovak Ophthalmology
2012 Číslo 1
Najčítanejšie v tomto čísle
- Gases in Vitreoretinal Surgery
- Floppy Eyelid Syndrome and Obstructive Sleep Apnoea
- Selected Prognostic Factors of Malignant Uveal Melanoma
- Comparative Study of Intraocular Pressure Measurements by Goldmann Applanation Tonometer, Noncontact Tonometer and TonoPen